Placebo for CBP-0276

Phase 2

CClarent Biopharma, Inc.

Placebo for CBP-0276 is one of 45 therapeutic programs targeting Psoriasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

PsoriasisRecruiting

PsoriasisPhase 2

Recruiting

Competition

Competitive Landscape

102 competitors in Psoriasis

#DrugCompanyPhaseTrials

Daliresp

AstraZeneca

Phase 3

5 2

Zasocitinib

Takeda

Phase 3

1 3

D-2570

IInventisBio Co., Ltd

Phase 3

4 4

TAK-279

Takeda

Phase 3

3 5

SYHX1901

CCSPC Ouyi Pharmaceutical Co., Ltd.

Phase 3

2 6

Vunakizumab (IL-17A Inhibitor)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

1 7

SHR-1314

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

4 8

ICP-488

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

3 9

HS-10374

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

3 10

IDP-118 Lotion

BBausch Health Americas, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Knee1 trial

Proof-of-concept, Double-blind, Randomized Clinical Study to Evaluate the Safety and Efficacy of CBP-0276 at Doses of 600 mg/Day vs Placebo in Reducing Opioid Use in Pain Management in Adult Patients Undergoing Major Orthopedic Surgery

Recruiting·CClarent Biopharma, Inc.·Phase 2·NCT07687966·80 enrolled

Psoriasis1 trial

Safety and Efficacy of CBP-0276 200mg/Day Twice Dose a Day, or Placebo Administrated for 36 Weeks, to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects 18y to 70y: Randomized Controlled Trial

Recruiting·CClarent Biopharma, Inc.·Phase 2·NCT07204639·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Placebo for CBP-0276. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo for CBP-0276. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Clarent Biopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CClarent Biopharma, Inc.

Placebo for CBP-0276

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Knee1 trial

Psoriasis1 trial

References

Drug Info

Quick Facts

Related News